Fentanyl Reduction With Esketamine Changed the Whole Bronchoscopy Regimen

The elderly bronchoscopy trial tested a combined anesthetic strategy, so its oxygen findings cannot be assigned to remimazolam alone.

Study findings

In the 274-patient randomized trial, patients aged sixty-five to eighty-five received remimazolam-based sedation with either an esketamine-containing, reduced-fentanyl strategy or the comparator fentanyl strategy. Hypoxemia occurred in 2.19% versus 9.49%, and hypotension in 0.73% versus 18.25%. Awakening was faster with the study regimen, while discharge time and sedation success did not clearly differ. Salivation increased, without observed aspiration.

What limits the conclusion

Changing both the opioid exposure and the adjunct prevents this comparison from isolating one drug’s contribution. The study excluded important high-risk conditions, including baseline hypoxemia and severe cardiovascular disease. No observed aspiration in this sample does not establish that increased secretions are harmless in every airway.

Implications for case review

Review the full regimen when evaluating respiratory events during bronchoscopy: the opioid, esketamine, benzodiazepine, oxygen delivery and airway interventions all belong in the timeline. A lower benzodiazepine or opioid amount does not independently describe the combined effect. This source supports a specific regimen comparison in selected older patients, with a secretion tradeoff; it does not supply an individual threshold for safe sedation or establish why a particular patient desaturated.

Source and related reading

Source: PMC12665225, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.

Related: Bronchoscopy Comfort Findings Do Not Isolate Midazolam From Fentanyl or Baseline Anxiety.